CBC Group

Yaneng Biotechnology specializes in molecular diagnostic technology, focusing on gene diagnostic chip platforms. The company offers a range of services, including cervical cancer screening and hereditary disease diagnostics, which encompass pre-pregnancy and prenatal testing. Additionally, Yaneng Biotechnology provides automatic nucleic acid extraction and conducts research and development services. Their portfolio also includes molecular diagnosis solutions and medical laboratory services aimed at addressing conditions such as cervical cancer and hepatitis.

Developer of mRNA platform designed to build a diverse pipeline of innovative medicines. The company provides end-to-end GMP manufacturing capabilities, MSAT infrastructure for process scale-up and tech transfer, and develops single and multi-mRNA/DNA products, enabling healthcare professionals to tackle infectious diseases.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.

I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.

I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.

NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.

Anrei Medical Co., Ltd. is a manufacturer based in Hangzhou, China, specializing in the development, production, and distribution of disposable medical devices designed for minimally invasive procedures. Established in 2006, the company offers a diverse range of products, including stent systems and gastrointestinal tools such as cytology brushes, biopsy forceps, and endoscopy accessories. Additionally, Anrei Medical provides various ERCP accessories and early cancer treatment devices, such as hot biopsy forceps and retrieval nets. Its extensive sales network spans China, North America, Europe, and South Asia, allowing the company to reach a broad market. As a fully owned and FDA-registered enterprise, Anrei Medical is committed to quality and innovation in the medical device sector.

Ascletis Pharma Inc. is a biotechnology company focused on the research, development, manufacture, marketing, and sale of pharmaceutical products, primarily in Mainland China and internationally. The company offers several antiviral treatments, including Ganovo for hepatitis C, Pegasys for hepatitis B and C, and Ravidasvir, a pan-genotypic NS5A inhibitor for HCV. Its product pipeline features ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor for non-alcoholic steatohepatitis (NASH) also in Phase II readiness, and ASC41, an oral THR-ß agonist for NASH. Additionally, Ascletis is advancing therapies such as ASC09, a protease inhibitor that has completed Phase IIA trials for HIV, and ASC06, which has finished Phase I trials for liver cancer. The company is also exploring treatments in pre-clinical stages for hepatitis B and NASH. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to create a sustainable business model through innovative drug development and commercialization strategies tailored to the growing Chinese pharmaceutical market.

I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.

FitSAMO is an orthopaedic surgical equipment supplier.

Ascletis Pharma Inc. is a biotechnology company focused on the research, development, manufacture, marketing, and sale of pharmaceutical products, primarily in Mainland China and internationally. The company offers several antiviral treatments, including Ganovo for hepatitis C, Pegasys for hepatitis B and C, and Ravidasvir, a pan-genotypic NS5A inhibitor for HCV. Its product pipeline features ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor for non-alcoholic steatohepatitis (NASH) also in Phase II readiness, and ASC41, an oral THR-ß agonist for NASH. Additionally, Ascletis is advancing therapies such as ASC09, a protease inhibitor that has completed Phase IIA trials for HIV, and ASC06, which has finished Phase I trials for liver cancer. The company is also exploring treatments in pre-clinical stages for hepatitis B and NASH. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to create a sustainable business model through innovative drug development and commercialization strategies tailored to the growing Chinese pharmaceutical market.

FitSAMO is an orthopaedic surgical equipment supplier.

Clarus Therapeutics, Inc. is a pharmaceutical company based in Northbrook, Illinois, specializing in men's health. Founded in 2003, the company develops and commercializes androgen-based therapies, primarily focusing on oral testosterone replacement. Its flagship product, JATENZO, is a soft gel formulation of testosterone undecanoate designed to treat men with low testosterone levels, a condition known as hypogonadism. JATENZO is notable for being the first and only oral testosterone replacement therapy approved for use in the United States, making it a significant innovation in the field. The company generates its revenue solely from the commercialization of this product.